China Resources Boya Bio pharmaceutical Group Co Ltd (300294) — Net Asset Quality Index
China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has a Net Asset Quality Index of 88.8% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥8.41 Billion minus total liabilities of CN¥942.80 Million yields net assets of CN¥7.46 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 300294 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
China Resources Boya Bio pharmaceutical Group Co Ltd Net Asset Quality Index Over Time (2008–2025)
This chart shows how China Resources Boya Bio pharmaceutical Group Co Ltd's Net Asset Quality Index has evolved across 18 annual periods from 2008 to 2025. As of March 2026, the index stands at 88.8%, representing net assets of CN¥7.46 Billion against total assets of CN¥8.41 Billion CNY. See China Resources Boya Bio pharmaceutical working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for China Resources Boya Bio pharmaceutical Group Co Ltd (2008–2025)
The table below presents the year-by-year Net Asset Quality Index for China Resources Boya Bio pharmaceutical Group Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 300294 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 86.5% | CN¥7.46 Billion | CN¥8.63 Billion | CN¥1.16 Billion | ▼ -2.6 pp |
| 2024 | 89.1% | CN¥7.49 Billion | CN¥8.40 Billion | CN¥913.38 Million | ▼ -4.4 pp |
| 2023 | 93.5% | CN¥7.32 Billion | CN¥7.83 Billion | CN¥508.07 Million | ▲ +2.8 pp |
| 2022 | 90.7% | CN¥7.28 Billion | CN¥8.03 Billion | CN¥748.35 Million | ▼ -0.1 pp |
| 2021 | 90.8% | CN¥6.92 Billion | CN¥7.62 Billion | CN¥701.30 Million | ▲ +9.5 pp |
| 2020 | 81.3% | CN¥4.19 Billion | CN¥5.16 Billion | CN¥966.08 Million | ▲ +5.4 pp |
| 2019 | 75.9% | CN¥3.99 Billion | CN¥5.26 Billion | CN¥1.27 Billion | ▲ +1.6 pp |
| 2018 | 74.3% | CN¥3.77 Billion | CN¥5.07 Billion | CN¥1.30 Billion | ▲ +6.6 pp |
| 2017 | 67.7% | CN¥2.48 Billion | CN¥3.67 Billion | CN¥1.19 Billion | ▼ -20.4 pp |
| 2016 | 88.1% | CN¥2.13 Billion | CN¥2.42 Billion | CN¥287.30 Million | ▲ +0.9 pp |
| 2015 | 87.2% | CN¥1.91 Billion | CN¥2.19 Billion | CN¥280.11 Million | ▼ -3.6 pp |
| 2014 | 90.8% | CN¥923.93 Million | CN¥1.02 Billion | CN¥93.90 Million | ▲ +6.5 pp |
| 2013 | 84.3% | CN¥846.62 Million | CN¥1.00 Billion | CN¥157.85 Million | ▼ -12.4 pp |
| 2012 | 96.7% | CN¥751.60 Million | CN¥777.41 Million | CN¥25.80 Million | ▲ +17.4 pp |
| 2011 | 79.3% | CN¥262.67 Million | CN¥331.15 Million | CN¥68.48 Million | ▲ +12.4 pp |
| 2010 | 66.9% | CN¥197.44 Million | CN¥295.23 Million | CN¥97.79 Million | ▲ +14.9 pp |
| 2009 | 52.0% | CN¥164.49 Million | CN¥316.43 Million | CN¥151.93 Million | ▲ +9.3 pp |
| 2008 | 42.7% | CN¥63.79 Million | CN¥149.28 Million | CN¥85.49 Million | — |